Pioneering Pain-free Solutions
We leverage the power of technology to develop transformative, accurate solutions that improve quality of life.
We're on a mission to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life.
Our Technology
revolutionizing portable testing through fingertip sweat analysis
Our cutting-edge intelligent drug screening system detects commonly abused drugs via the fingertips. The system’s ease of use and portability make it a convenient solution for reliable drug screening and potential misuse within the 16 hours before testing.
INTELLIGENT DRUG SCREENING
A Dignified Approach to Testing
Our Intelligent Drug Screening system tests fingertip sweat for recent drug use, including cannabis, cocaine, opiates, and methamphetamine. Samples are collected in less than one minute and results displayed in less than ten minutes.
THE BIOSENSOR PLATFORM
A Platform for Multiple Diagnostic Tests
The biosensor platform is a small, printable organic strip designed to put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners.
News Updates
Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
NEW YORK, February 28, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership
Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’ Equity Requirement
NEW YORK, February 16, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that on
Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights
Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023. Expanded into New Zealand market and increased market share in existing regions.